TY - JOUR
T1 - Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids
T2 - Results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL)
AU - Di Renzo, Nicola
AU - Montanini, Antonella
AU - Mannina, Donato
AU - Dondi, Alessandra
AU - Muci, Stefania
AU - Mancuso, Salvatrice
AU - De Paolis, M. Rosaria
AU - Plati, Caterina
AU - Stelitano, Caterina
AU - Patti, Catia
AU - Olivieri, Attilio
AU - Liardo, Eliana
AU - Buda, Gabriele
AU - Cantaffa, Renato
AU - Federico, Massimo
PY - 2011/10
Y1 - 2011/10
N2 - Purpose: The control of nausea and vomiting induced by chemotherapy is paramount for overall treatment success in cancer patients. Antiemetic therapy during chemotherapy in lymphoma patients generally consists of anti-serotoninergic drugs and dexamethasone. The aim of this trial was to evaluate the efficacy of a single dose of palonosetron, a second-generation serotonin type 3 (5-HT 3) receptor antagonist, in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy (MEC) containing steroids. Methods: Patients received a single intravenous bolus of palonosetron (0.25 mg) before administration of chemotherapy. Complete response (CR) defined as no vomiting and no rescue therapy during overall phase (0-120 h) was the primary endpoint. Complete control (CC) defined as CR and only mild nausea was a secondary endpoint. Results: Eighty-six evaluable patients entered in the study. A CR was observed in 74 patients (86.0%) during the overall phase; the CR during the acute (0-24 h) and delayed (24-120 h) phases was 90.7% and 88.4%, respectively. CC was 89.5% during the acute and 84.9% during the delayed phase; the overall CC was 82.6%. Conclusions: This was the first trial, which demonstrated the efficacy of a single dose of palonosetron in control CINV in patients with aggressive non-Hodgkin's lymphoma receiving MEC regimen containing steroids.
AB - Purpose: The control of nausea and vomiting induced by chemotherapy is paramount for overall treatment success in cancer patients. Antiemetic therapy during chemotherapy in lymphoma patients generally consists of anti-serotoninergic drugs and dexamethasone. The aim of this trial was to evaluate the efficacy of a single dose of palonosetron, a second-generation serotonin type 3 (5-HT 3) receptor antagonist, in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy (MEC) containing steroids. Methods: Patients received a single intravenous bolus of palonosetron (0.25 mg) before administration of chemotherapy. Complete response (CR) defined as no vomiting and no rescue therapy during overall phase (0-120 h) was the primary endpoint. Complete control (CC) defined as CR and only mild nausea was a secondary endpoint. Results: Eighty-six evaluable patients entered in the study. A CR was observed in 74 patients (86.0%) during the overall phase; the CR during the acute (0-24 h) and delayed (24-120 h) phases was 90.7% and 88.4%, respectively. CC was 89.5% during the acute and 84.9% during the delayed phase; the overall CC was 82.6%. Conclusions: This was the first trial, which demonstrated the efficacy of a single dose of palonosetron in control CINV in patients with aggressive non-Hodgkin's lymphoma receiving MEC regimen containing steroids.
KW - CHOP
KW - CINV
KW - Emesis
KW - Nausea
KW - NHL
KW - Palonosetron
UR - http://www.scopus.com/inward/record.url?scp=80052489830&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052489830&partnerID=8YFLogxK
U2 - 10.1007/s00520-010-0974-y
DO - 10.1007/s00520-010-0974-y
M3 - Article
C2 - 20694798
AN - SCOPUS:80052489830
VL - 19
SP - 1505
EP - 1510
JO - Supportive Care in Cancer
JF - Supportive Care in Cancer
SN - 0941-4355
IS - 10
ER -